Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.
{"title":"Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies.","authors":"Kentaro Nakai, Keiji Kono, Shunsuke Yamada, Masatomo Taniguchi, Takayuki Hamano, Masafumi Fukagawa","doi":"10.1111/1744-9987.14125","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis.</p><p><strong>Methods: </strong>A systematic literature search through October 2023 and a meta-analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included.</p><p><strong>Results: </strong>Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.</p><p><strong>Conclusion: </strong>Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.</p>","PeriodicalId":94253,"journal":{"name":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","volume":" ","pages":"557-571"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1111/1744-9987.14125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/18 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Several calcimimetics, other than cinacalcet, are commercially available; however, their effects on calcium and phosphate levels have not yet been fully studied. We conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the impact of calcimimetics on the management of serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis.
Methods: A systematic literature search through October 2023 and a meta-analysis were conducted on the effects of upacicalcet, etelcalcetide, evocalcet, and cinacalcet on serum calcium and phosphate levels in patients with secondary hyperparathyroidism undergoing dialysis; we searched PubMed, Ovid MEDLINE, and the Cochrane Central Register of Controlled Trials, and 21 studies comprising 6371 patients undergoing dialysis were included.
Results: Participants treated with calcimimetics had lower serum calcium and phosphate levels than placebo.
Conclusion: Calcimimetics significantly reduced serum calcium and phosphate levels compared to placebo in patients with secondary hyperparathyroidism undergoing dialysis, independent of therapeutic strategy or concomitant vitamin D treatment.
介绍：除西那钙外，市面上还有几种降钙药，但它们对钙和磷酸盐水平的影响尚未得到充分研究。我们对随机对照试验进行了系统回顾和荟萃分析，以评估降钙剂对透析治疗继发性甲状旁腺功能亢进患者血清钙和磷酸盐水平管理的影响：方法：我们检索了PubMed、Ovid MEDLINE和Cochrane对照试验中央登记册，对截至2023年10月的文献进行了系统检索，并对upacicalcet、etelcalcetide、evocalcet和cinacalcet对接受透析的继发性甲状旁腺功能亢进症患者血清钙和磷酸盐水平的影响进行了荟萃分析，共纳入21项研究，包括6371名接受透析的患者：结果：与安慰剂相比，接受降钙药治疗的患者血清钙和磷酸盐水平更低：结论：与安慰剂相比，降钙药能明显降低接受透析治疗的继发性甲状旁腺功能亢进症患者的血清钙和磷酸盐水平，与治疗策略或同时接受维生素 D 治疗无关。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
